Table of Contents

Wegovy (semaglutide) has helped thousands of people lose weight, but a few have noticed unexpected changes in their vision. Reports of blurry vision, dry eyes, and even mentions of “Wegovy blindness” have begun circulating in online communities.

While these eye-related side effects are uncommon, understanding how they happen and what to look out for can help you act early and protect your sight.

Here’s what research and real-world reports reveal about possible Wegovy eye side effects, why they occur, and when to get help.

Key Takeaways

  • Temporary blurry vision can happen when blood sugar improves quickly on Wegovy.
  • Diabetic retinopathy may temporarily worsen in people with existing eye disease as blood sugar control improves too fast.
  • Rare optic nerve damage (NAION) has been reported, causing sudden vision loss in isolated cases.
  • Some studies suggest a link to macular degeneration, but current evidence only shows an association, not a direct cause.
  • Extremely rare nerve-related effects, like reversible blind spots, have appeared in a few case reports.

Wegovy Eye Side Effects Reported by Users

Below are eye-related issues that some people have experienced while using Wegovy, based on current evidence and case reports.

1. Temporary blurred vision

Temporary blurred vision

Some users notice blurred or shifting vision soon after starting Wegovy or when their dose increases. This usually isn’t caused by the drug itself but by how quickly your blood sugar improves, which Wegovy can help with.

Quick improvements in blood sugar can cause the eye’s lens to swell or shrink slightly. That temporary change in lens thickness alters how light bends through the eye, making your sight a bit more farsighted or nearsighted for a short while.

Once your blood sugar levels even out, your vision usually returns to normal within a few days or weeks.

A study on people with diabetes showed that after starting insulin, all participants became temporarily more farsighted. On average, their vision changed by about +1.60 diopters (ranging from +0.50 to +3.20), but things went back to normal within two to four weeks.

Other parts of the eye, like pressure, shape, or cornea, didn’t change much, suggesting the issue came from the lens’ refractive changes, not the eye’s physical structure.

So if you have diabetes and your blood sugar is improving quickly on Wegovy, short-term blurriness is a possible but reversible side effect.

2. Early worsening of diabetic retinopathy

“Early worsening” of diabetic retinopathy is a known reaction that can happen when blood sugar levels improve quickly. Wegovy’s effect on blood glucose can trigger this in people who already have diabetic eye disease.

This pattern has been recognized since the 1980s, when some people with type 1 diabetes experienced a short-term worsening of retinopathy within 3-6 months of switching to intensive insulin therapy.

This doesn’t mean Wegovy causes retinopathy. It means that when blood sugar drops rapidly, existing eye damage can temporarily worsen. Because of this, Wegovy’s label advises extra monitoring for anyone who already has diabetic retinopathy or other vision problems.

3. Non-arteritic anterior ischemic optic neuropathy (NAION)

There have been case reports of NAION, a sudden and often permanent form of vision loss, in people using Wegovy.

Case 1: 47-year-old man

A 47-year-old man developed optic nerve swelling and partial vision loss in one eye after nearly a year on Wegovy.

He had no major eye problems aside from farsightedness (+5.00 glasses). He was obese and had lost about 18 kg (~ 40 lbs) during treatment. He had been using the 2.4 mg weekly dose for six months when he noticed increasing blurriness over three days.

Examination showed optic disc swelling consistent with NAION.

Case 2: 63-year-old man

Another patient, aged 63, experienced a dark shadow in the lower field of vision in his left eye, which worsened over five days.

He had undergone laser repair for a small retinal tear and cataract surgery in both eyes three weeks earlier. He also had hypertension, high cholesterol, and obesity, and had been using Wegovy for five months (1.7 mg weekly).

Eye exam revealed optic nerve swelling and partial vision loss typical of NAION.

Case 3: 55-year-old man

A 55-year-old man went to an eye clinic after noticing progressive blurring in the lower visual field of his right eye for five days.

His history included a mild episode of anterior uveitis but no other eye diseases. His only medical issue was obesity, and he had been using Wegovy for eight months, with 1.7 mg weekly injections for the last six months.

Tests showed optic disc edema and peripapillary fluid, consistent with NAION.

In all three cases, other factors such as prior eye surgery, vascular disease, or inflammation could have contributed, making it difficult to prove Wegovy as the sole cause.

Evidence from large studies

Large studies have also tried to explore the connection.

In a Denmark study, among over 424,000 people with type 2 diabetes, 67 out of 106,000 semaglutide users developed NAION, about twice the risk of non-users, but still rare (roughly 2 in 10,000 people per year).

Another hospital-based study found that semaglutide users were four times more likely to develop NAION than those taking other diabetes drugs.

In a review of 37 million patients, the annual risk was 0.0145%, and most comparisons didn’t show a significant difference versus other medications.

Experts emphasize that many people prescribed GLP-1 drugs already have health conditions, like diabetes, hypertension, or sleep apnea, that can independently raise the risk.

Although evidence is still evolving, the European Medicines Agency (EMA) and World Health Organization (WHO) have recommended listing NAION as a potential adverse effect on all semaglutide products, including Wegovy, Ozempic, and Rybelsus.

4. Neovascular age-related macular degeneration (nAMD)

Neovascular age-related macular degeneration

Another emerging concern is a possible link between semaglutide and neovascular age-related macular degeneration (nAMD). This eye disease occurs when fragile new blood vessels form under the retina and leak fluid or blood, leading to swelling, scarring, and loss of central vision.

Common symptoms include:

    • Blurry or distorted central vision
    • Straight lines appearing wavy
    • Dark or blank spots in the center
    • Sudden drop in vision clarity

A retrospective study following 138,000 adults with diabetes aged 66 or older found that 0.2 % of GLP-1 users (mostly semaglutide) developed nAMD within three years, compared with 0.1 % of non-users.

After adjusting for other variables, the relative risk appeared about 2.2 times higher, but researchers stress that this shows an association, not proof that semaglutide causes macular degeneration.

5. Neuro-ophthalmic effects (rare)

Sometimes, vision problems can come from how the optic nerve or brain processes visual signals, rather than from the eye itself.

A case report described a 72-year-old man taking high-dose oral semaglutide (Rybelsus 3 mg daily) for weight loss. After 17 days, he noticed a small central blind spot (scotoma) in his right eye that slowly enlarged, followed by a similar one in his left.

The blind spots appeared only in dim light, and not in daylight or normal room lighting. When he stopped taking semaglutide, both spots disappeared within two days.

This was the first documented case of reversible, light-dependent scotomas linked to semaglutide, but the cause remains uncertain.

What to Do If You Notice Eye Changes on Wegovy

Your eyes are delicate, and even small changes can be early warnings of something serious. Here’s what to do if you experience vision issues while on Wegovy:

  • Don’t ignore any changes – Even mild blurring, dryness, or wavy vision can signal early eye damage. Since some conditions, like optic nerve injury or worsening retinopathy, can lead to permanent vision loss, it’s best to act quickly. Get emergency care if you have:
        • Sudden vision loss in one eye
        • A dark curtain or shadow across vision
        • Persistent double vision
        • Flashes of light with new floaters
        • Dimmed or faded vision after waking
    These need immediate ER evaluation. Call an eye specialist the same day if you have:
        • New blind spots or distorted central vision
        • Severe dryness or eye pain that doesn’t improve
    Tell the clinic you’re taking Wegovy and that your symptoms began after starting or increasing your dose. An eye specialist will check your vision, pupils, and retina, often using imaging tests like OCT (optical coherence tomography) to detect swelling or bleeding behind the eye.
  • Inform your prescribing doctor – Your main doctor should know about any eye symptoms. They may temporarily pause your Wegovy treatment until an ophthalmologist clears you to continue.
  • Prevention and follow-up – If you have diabetes, continue with regular annual dilated eye exams, and schedule an extra visit after starting or increasing Wegovy, especially if you already have retinopathy. Keeping blood sugar, cholesterol, and blood pressure stable, along with good hydration, helps reduce the risk of complications.

To sum it up

Most people taking Wegovy never experience serious vision problems.

If you notice blurred vision, new floaters, or sudden shadows in your visual field, don’t wait for it to pass. Schedule an eye exam right away and inform your doctor that you’re using Wegovy. Early evaluation can prevent lasting damage and ensure your treatment remains safe and effective.

For ongoing prevention, keep your blood pressure, cholesterol, and glucose well-controlled, and follow up regularly with your ophthalmologist. Wegovy can be an effective tool for weight management, but your eye health deserves equal attention along the way.

Related Articles

Frequently Asked Questions

Most side effects of Wegovy, like nausea, diarrhea, and vomiting, tend to improve as your body adjusts to the medication. This adjustment usually happens within a few weeks or months, especially if the dose is increased gradually. If symptoms persist or worsen, your doctor may suggest slowing down dose increases or taking a temporary break.

The most frequently reported side effect is nausea. Many people also experience vomiting, diarrhea, constipation, or stomach discomfort, especially when first starting or increasing the dose.

Wegovy is not recommended for people with a personal or family history of medullary thyroid carcinoma (MTC) or those with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It’s also not suitable for anyone with a past severe allergic reaction to semaglutide or its ingredients. Pregnant individuals or those planning pregnancy should avoid it since it may harm the baby.

Wegovy is generally meant for long-term weight management. People usually stay on it as long as it continues to help maintain weight loss and doesn’t cause serious side effects. Stopping suddenly may cause weight regain, so your doctor may guide you on how to taper off safely if needed.

If you miss a weekly dose and your next scheduled injection is more than two days away, take the missed dose as soon as you remember. If it’s less than two days before your next dose, skip it and continue your regular schedule. Avoid doubling doses to make up for a missed one, as that can increase the risk of side effects.

Sources

Li, H., Luo, G., Guo, J., & Liang, Z. (2010). Effects of glycemic control on refraction in diabetic patients. PubMed. https://doi.org/10.3980/j.issn.2222-3959.2010.02.15

Bain, S. C., Klufas, M. A., Ho, A., & Matthews, D. R. (2018). Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: A review. Diabetes Obesity and Metabolism, 21(3), 454–466. https://doi.org/10.1111/dom.13538

Ahmadi, H., & Hamann, S. (2025). Anterior ischemic optic neuropathy in patients treated with semaglutide: report of four cases with a possible association. BMC Ophthalmology, 25(1). https://doi.org/10.1186/s12886-025-03958-4

Grauslund, J., Taha, A. A., Molander, L. D., Kawasaki, R., Möller, S., Højlund, K., & Stokholm, L. (2024). Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes. International Journal of Retina and Vitreous, 10(1). https://doi.org/10.1186/s40942-024-00620-x

Hathaway, J. T., Shah, M. P., Hathaway, D. B., Zekavat, S. M., Krasniqi, D., Gittinger, J. W., Cestari, D., Mallery, R., Abbasi, B., Bouffard, M., Chwalisz, B. K., Estrela, T., & Rizzo, J. F. (2024). Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide. JAMA Ophthalmology, 142(8), 732. https://doi.org/10.1001/jamaophthalmol.2024.2296

Cai, C. X., Hribar, M., Baxter, S., Goetz, K., Swaminathan, S. S., Flowers, A., Brown, E. N., Toy, B., Xu, B., Chen, J., Chen, A., Wang, S., Lee, C., Leng, T., Ehrlich, J. R., Barkmeier, A., Armbrust, K. R., Boland, M. V., Dorr, D., . . . Ryan, P. B. (2025). Semaglutide and nonarteritic anterior ischemic optic neuropathy. JAMA Ophthalmology. https://doi.org/10.1001/jamaophthalmol.2024.6555

PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy | European Medicines Agency (EMA). (2025, June 13). European Medicines Agency (EMA). https://www.ema.europa.eu/en/news/prac-concludes-eye-condition-naion-very-rare-side-effect-semaglutide-medicines-ozempic-rybelsus-wegovy

Shor, R., Mihalache, A., Noori, A., Shor, R., Kohly, R. P., Popovic, M. M., & Muni, R. H. (2025). Glucagon-Like peptide-1 receptor agonists and risk of neovascular Age-Related macular degeneration. JAMA Ophthalmology, 143(7), 587. https://doi.org/10.1001/jamaophthalmol.2025.1455

Bracha, P., Johnson, W., Chu, S., & Davison, J. (2024). Reversible bilateral central scotoma under scotopic conditions associated with oral semaglutide. American Journal of Ophthalmology Case Reports, 36, 102121. https://doi.org/10.1016/j.ajoc.2024.102121

Does semaglutide increase the risk of nonarteritic anterior ischemic optic neuropathy? (n.d.). AHA Blogs. https://www.ahajournals.org/do/10.1161/blog.20240806.153395